Additional file 1 of An ex-ante cost-utility analysis of the deemed consent legislation compared to expressed consent for kidney transplantations in Nova Scotia

Additional file 1: Table S1. Cost-effectiveness analysis results for various changes in deceased donor kidney transplantation probability. Table S2. Cost-effectiveness analyses result for various percentage changes in living donor kidney transplantation probability, assuming a 1% increase in deceased donor kidney transplantation probability. Table S3. Cost-effectiveness analyses result for various percentage changes in living donor kidney transplantation probability, assuming a 26% increase in deceased donor kidney transplantation probability. Figure S1. Cost-effectiveness acceptability curve for a 26% increase in deceased donor kidney transplantation probability. Figure S2. Cost-effectiveness plane for a 26% increase in deceased donor kidney transplantation probability. Figure S3. The sensitivity of ICUR to changes in dialysis and maintenance immunosuppressant drug costs for a 26% increase in deceased donor KT probability. ICUR, incremental cost-utility ratio; QALY, quality-adjusted life-year; WTP, willingness to pay; KT, kidney transplantation; HD, hemodialysis; PD, peritoneal dialysis; EV expected value

Additional file 1 of Reducing wait times and avoiding unnecessary use of high-cost mental health services through a Rapid Access and Stabilization Program: protocol for a program evaluation study

Additional file 1: Table S1. Gantt chart timeline for Study 1